-
1
-
-
0003964363
-
-
American Cancer Society: Atlant, GA, USA
-
American Cancer Society. Cancer Facts & Figures 2013. American Cancer Society: Atlant, GA, USA, 2013.
-
(2013)
Cancer Facts & Figures 2013
-
-
-
2
-
-
84867539636
-
RAS/ RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy
-
Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O et al. RAS/ RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012; 2012: 1-5.
-
(2012)
Dermatol Res Pract
, vol.2012
, pp. 1-5
-
-
Yajima, I.1
Kumasaka, M.Y.2
Thang, N.D.3
Goto, Y.4
Takeda, K.5
Yamanoshita, O.6
-
3
-
-
83455218210
-
Molecular targeted therapy in melanoma: A way to reverse resistance to conventional drugs
-
Maira F, Catania A, Candido S, Russo AE, McCubrey JA, Libra M et al. Molecular targeted therapy in melanoma: A way to reverse resistance to conventional drugs. Curr Drug Deliv 2012; 9: 17-29.
-
(2012)
Curr Drug Deliv
, vol.9
, pp. 17-29
-
-
Maira, F.1
Catania, A.2
Candido, S.3
Russo, A.E.4
McCubrey, J.A.5
Libra, M.6
-
4
-
-
33947213963
-
Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma
-
Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007; 67: 2298-2305.
-
(2007)
Cancer Res
, vol.67
, pp. 2298-2305
-
-
Namkoong, J.1
Shin, S.S.2
Lee, H.J.3
Marín, Y.E.4
Wall, B.A.5
Goydos, J.S.6
-
5
-
-
0037994016
-
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia
-
Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003; 34: 108-112.
-
(2003)
Nat Genet
, vol.34
, pp. 108-112
-
-
Pollock, P.M.1
Cohen-Solal, K.2
Sood, R.3
Namkoong, J.4
Martino, J.J.5
Koganti, A.6
-
6
-
-
43549096176
-
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation
-
Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res 2008; 21: 368-378.
-
(2008)
Pigment Cell Melanoma Res
, vol.21
, pp. 368-378
-
-
Shin, S.S.1
Namkoong, J.2
Wall, B.A.3
Gleason, R.4
Lee, H.J.5
Chen, S.6
-
7
-
-
79953316415
-
Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo
-
Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM et al. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 2011; 17: 1807-1814.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1807-1814
-
-
Khan, A.J.1
Wall, B.2
Ahlawat, S.3
Green, C.4
Schiff, D.5
Mehnert, J.M.6
-
8
-
-
49949117480
-
Metabotropic glutamate receptors (mGluRs) and cellular transformation
-
Shin SS, Martino JJ, Chen S. Metabotropic glutamate receptors (mGluRs) and cellular transformation. Neuropharmacology 2008; 55: 396-402.
-
(2008)
Neuropharmacology
, vol.55
, pp. 396-402
-
-
Shin, S.S.1
Martino, J.J.2
Chen, S.3
-
10
-
-
57349145304
-
Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma
-
Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, Abdel-Daim M et al. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene 2008; 27: 7162-7170.
-
(2008)
Oncogene
, vol.27
, pp. 7162-7170
-
-
Ohtani, Y.1
Harada, T.2
Funasaka, Y.3
Nakao, K.4
Takahara, C.5
Abdel-Daim, M.6
-
11
-
-
77955715672
-
The glutamate release inhibitor riluzole decreases migration, invasion, and proliferation of melanoma cells
-
Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA et al. The glutamate release inhibitor riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 2010; 130: 2240-2249.
-
(2010)
J Invest Dermatol
, vol.130
, pp. 2240-2249
-
-
Le, M.N.1
Chan, J.L.2
Rosenberg, S.A.3
Nabatian, A.S.4
Merrigan, K.T.5
Cohen-Solal, K.A.6
-
12
-
-
0030995878
-
Pharmacology and functions of metabotropic glutamate receptors
-
Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997; 37: 205-237.
-
(1997)
Annu Rev Pharmacol Toxicol
, vol.37
, pp. 205-237
-
-
Conn, P.J.1
Pin, J.P.2
-
13
-
-
0028912822
-
The metabotropic glutamate receptors: Structure and functions
-
Pin JP, Duvoisin R. The metabotropic glutamate receptors: Structure and functions. Neuropharmacology 1995; 34: 1-26.
-
(1995)
Neuropharmacology
, vol.34
, pp. 1-26
-
-
Pin, J.P.1
Duvoisin, R.2
-
15
-
-
84859107394
-
Metabotropic glutamate receptor-1: A potential therapeutic target for the treatment of breast cancer
-
Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH. Metabotropic glutamate receptor-1: A potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 2012; 132: 565-573.
-
(2012)
Breast Cancer Res Treat
, vol.132
, pp. 565-573
-
-
Speyer, C.L.1
Smith, J.S.2
Banda, M.3
Devries, J.A.4
Mekani, T.5
Gorski, D.H.6
-
16
-
-
84896762683
-
Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer
-
Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres KE et al. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS ONE 2014; 9: 1-12.
-
(2014)
PLoS ONE
, vol.9
, pp. 1-12
-
-
Banda, M.1
Speyer, C.L.2
Semma, S.N.3
Osuala, K.O.4
Kounalakis, N.5
Torres, K.E.6
-
17
-
-
18244393785
-
Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance
-
Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 2005; 11: 3288-3295.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3288-3295
-
-
Chang, H.J.1
Yoo, B.C.2
Lim, S.B.3
Jeong, S.Y.4
Kim, W.H.5
Park, J.G.6
-
18
-
-
77953726117
-
Glutamate receptors in pediatric tumors of the central nervous system
-
Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010; 9: 455-468.
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 455-468
-
-
Brocke, K.S.1
Staufner, C.2
Luksch, H.3
Geiger, K.D.4
Stepulak, A.5
Marzahn, J.6
-
19
-
-
39049193970
-
Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma
-
Park SY, Lee SA, Han IH, Yoo BC, Lee SH, Park JY et al. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol Rep 2007; 17: 81-87.
-
(2007)
Oncol Rep
, vol.17
, pp. 81-87
-
-
Park, S.Y.1
Lee, S.A.2
Han, I.H.3
Yoo, B.C.4
Lee, S.H.5
Park, J.Y.6
-
20
-
-
79957897718
-
Glutamate and the biology of gliomas
-
De Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia 2011; 59: 1181-1189.
-
(2011)
Glia
, vol.59
, pp. 1181-1189
-
-
De Groot, J.1
Sontheimer, H.2
-
21
-
-
0033198997
-
Glioma cells release excitotoxic concentrations of glutamate
-
Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999; 59: 4383-4391.
-
(1999)
Cancer Res
, vol.59
, pp. 4383-4391
-
-
Ye, Z.C.1
Sontheimer, H.2
-
22
-
-
35148854098
-
Autocrine glutamate signaling promotes glioma cell invasion
-
Lyons SA, Chung WJ, Weaver AK, Ogunrinu T, Sontheimer H. Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 2007; 67: 9463-9471.
-
(2007)
Cancer Res
, vol.67
, pp. 9463-9471
-
-
Lyons, S.A.1
Chung, W.J.2
Weaver, A.K.3
Ogunrinu, T.4
Sontheimer, H.5
-
23
-
-
81255195907
-
Glutamatergic pathway targeting in melanoma: Single-agent and combinatorial therapies
-
Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL et al. Glutamatergic pathway targeting in melanoma: Single-agent and combinatorial therapies. Clin Cancer Res 2011; 17: 7080-7092.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7080-7092
-
-
Lee, H.J.1
Wall, B.A.2
Wangari-Talbot, J.3
Shin, S.S.4
Rosenberg, S.5
Chan, J.L.6
-
24
-
-
78650309875
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
-
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson La et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.
-
(2010)
Nature
, vol.468
, pp. 968-972
-
-
Johannessen, C.M.1
Boehm, J.S.2
Kim, S.Y.3
Thomas, S.R.4
Wardwell, L.5
Johnson, L.A.6
-
25
-
-
84875632487
-
Two newly identified exons in human GRM1 express a novel splice variant of metabotropic glutamate 1 receptor
-
DiRaddo JO, Pshenichkin S, Gelb T, Wroblewski JT. Two newly identified exons in human GRM1 express a novel splice variant of metabotropic glutamate 1 receptor. Gene 2013; 519: 367-373.
-
(2013)
Gene
, vol.519
, pp. 367-373
-
-
Diraddo, J.O.1
Pshenichkin, S.2
Gelb, T.3
Wroblewski, J.T.4
-
27
-
-
0034057273
-
Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes
-
Frati C, Marchese C, Fisichella G, Copani A, Nasca MR, Storto M et al. Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes. J Cell Physiol 2000; 183: 364-372.
-
(2000)
J Cell Physiol
, vol.183
, pp. 364-372
-
-
Frati, C.1
Marchese, C.2
Fisichella, G.3
Copani, A.4
Nasca, M.R.5
Storto, M.6
-
28
-
-
84900005185
-
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression
-
Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS et al. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Res. 2014; 74: 2499-2509.
-
(2014)
Cancer Res.
, vol.74
, pp. 2499-2509
-
-
Wen, Y.1
Li, J.2
Koo, J.3
Shin, S.S.4
Lin, Y.5
Jeong, B.S.6
-
29
-
-
33745078628
-
Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function
-
Deng W, Yue Q, Rosenberg PA, Volpe JJ, Jensen FE. Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function. J Neurochem 2006; 98: 213-222.
-
(2006)
J Neurochem
, vol.98
, pp. 213-222
-
-
Deng, W.1
Yue, Q.2
Rosenberg, P.A.3
Volpe, J.J.4
Jensen, F.E.5
-
30
-
-
0026492817
-
Features of apoptotic cells measured by flow cytometry
-
Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
-
(1992)
Cytometry
, vol.13
, pp. 795-808
-
-
Darzynkiewicz, Z.1
Bruno, S.2
Del Bino, G.3
Gorczyca, W.4
Hotz, M.A.5
Lassota, P.6
-
31
-
-
80655129636
-
VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells
-
Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM et al. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biol Ther 2011; 12: 818-826.
-
(2011)
Cancer Biol Ther
, vol.12
, pp. 818-826
-
-
Ringer, L.1
Sirajuddin, P.2
Heckler, M.3
Ghosh, A.4
Suprynowicz, F.5
Yenugonda, V.M.6
-
32
-
-
8844229596
-
JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist
-
Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 2004; 47: 961-972.
-
(2004)
Neuropharmacology
, vol.47
, pp. 961-972
-
-
Lavreysen, H.1
Wouters, R.2
Bischoff, F.3
Nóbrega Pereira, S.4
Langlois, X.5
Blokland, S.6
-
33
-
-
84865069757
-
Molecular pathways: Dysregulated glutamatergic signaling pathways in cancer
-
Prickett TD, Samuels Y. Molecular pathways: Dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 2012; 18: 4240-4246.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4240-4246
-
-
Prickett, T.D.1
Samuels, Y.2
-
34
-
-
84884572685
-
Glutamate, glutamate receptors, and downstream signaling pathways
-
Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 2013; 9: 948-959.
-
(2013)
Int J Biol Sci
, vol.9
, pp. 948-959
-
-
Willard, S.S.1
Koochekpour, S.2
-
35
-
-
71849096345
-
Cancer cell lines release glutamate into the extracellular environment
-
Seidlitz EP, Sharma MK, Saikali Z, Ghert M, Singh G. Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis 2009; 26: 781-787.
-
(2009)
Clin Exp Metastasis
, vol.26
, pp. 781-787
-
-
Seidlitz, E.P.1
Sharma, M.K.2
Saikali, Z.3
Ghert, M.4
Singh, G.5
-
36
-
-
0034800265
-
Glutamate release promotes growth of malignant gliomas
-
Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010-1015.
-
(2001)
Nat Med
, vol.7
, pp. 1010-1015
-
-
Takano, T.1
Lin, J.H.2
Arcuino, G.3
Gao, Q.4
Yang, J.5
Nedergaard, M.6
-
37
-
-
84868560533
-
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells
-
Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D et al. Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res 2012; 18: 5888-5901.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5888-5901
-
-
Koochekpour, S.1
Majumdar, S.2
Azabdaftari, G.3
Attwood, K.4
Scioneaux, R.5
Subramani, D.6
-
38
-
-
85027946522
-
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
-
Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43: 442-446.
-
(2011)
Nat Genet
, vol.43
, pp. 442-446
-
-
Wei, X.1
Walia, V.2
Lin, J.C.3
Teer, J.K.4
Prickett, T.D.5
Gartner, J.6
-
39
-
-
35548984436
-
Genetic analysis of the GRM1 gene in human melanoma susceptibility
-
Ortiz P, Vanaclocha F, López-Bran E, Esquivias JI, López-Estebaranz JL, Martín-González M et al. Genetic analysis of the GRM1 gene in human melanoma susceptibility. Eur J Hum Genet 2007; 15: 1176-1182.
-
(2007)
Eur J Hum Genet
, vol.15
, pp. 1176-1182
-
-
Ortiz, P.1
Vanaclocha, F.2
López-Bran, E.3
Esquivias, J.I.4
López-Estebaranz, J.L.5
Martín-González, M.6
-
40
-
-
17744364264
-
Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test
-
(Berl
-
Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J et al. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005; 179: 198-206.
-
(2005)
Psychopharmacology
, vol.179
, pp. 198-206
-
-
Steckler, T.1
Lavreysen, H.2
Oliveira, A.M.3
Aerts, N.4
Van Craenendonck, H.5
Prickaerts, J.6
-
41
-
-
24344483151
-
Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task
-
Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X et al. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res 2005; 14: 52-60.
-
(2005)
Behav Brain Res
, vol.14
, pp. 52-60
-
-
Steckler, T.1
Oliveira, A.F.2
Van Dyck, C.3
Van Craenendonck, H.4
Mateus, A.M.5
Langlois, X.6
-
42
-
-
49949110710
-
Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor in conditions of trophic deprivation-possible role as a dependence receptor
-
Pshenichkin S, Doli?ska M, Klauzi?ska M, Luchenko V, Grajkowska E, Wroblewski JT. Dual neurotoxic and neuroprotective role of metabotropic glutamate receptor in conditions of trophic deprivation-possible role as a dependence receptor. Neuropharmacology 2008; 55: 500-508.
-
(2008)
Neuropharmacology
, vol.55
, pp. 500-508
-
-
Pshenichkin, S.1
Doliska, M.2
Klauziska, M.3
Luchenko, V.4
Grajkowska, E.5
Wroblewski, J.T.6
-
43
-
-
77950517630
-
Dependence receptors: A new paradigm in cell signaling and cancer therapy
-
Goldschneider D, Mehlen P. Dependence receptors: A new paradigm in cell signaling and cancer therapy. Oncogene 2010; 29: 1865-1882.
-
(2010)
Oncogene
, vol.29
, pp. 1865-1882
-
-
Goldschneider, D.1
Mehlen, P.2
-
44
-
-
42449139816
-
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
-
Fitamant J, Guenebeaud C, Coissieux MM, Guix C, Treilleux I, Scoazec JY et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci USA 2008; 105: 4850-4855.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 4850-4855
-
-
Fitamant, J.1
Guenebeaud, C.2
Coissieux, M.M.3
Guix, C.4
Treilleux, I.5
Scoazec, J.Y.6
-
45
-
-
60749089170
-
Interference with netrin-1 and tumor cell death in non-small cell lung cancer
-
Delloye-Bourgeois C, Brambilla E, Coissieux MM, Guenebeaud C, Pedeux R, Firlej V et al. Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J Natl Cancer Inst 2009; 101: 237-247.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 237-247
-
-
Delloye-Bourgeois, C.1
Brambilla, E.2
Coissieux, M.M.3
Guenebeaud, C.4
Pedeux, R.5
Firlej, V.6
-
46
-
-
65549164340
-
Netrin-1 acts as a survival factor for aggressive neuroblastoma
-
Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA et al. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med 2009; 206: 833-847.
-
(2009)
J Exp Med
, vol.206
, pp. 833-847
-
-
Delloye-Bourgeois, C.1
Fitamant, J.2
Paradisi, A.3
Cappellen, D.4
Douc-Rasy, S.5
Raquin, M.A.6
-
48
-
-
0141783841
-
Neuroprotection against NMDA excitotoxicity by group i metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents
-
Blaabjerg M, Fang L, Zimmer J, Baskys A. Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents. Exp Neurol 2003; 183: 573-580.
-
(2003)
Exp Neurol
, vol.183
, pp. 573-580
-
-
Blaabjerg, M.1
Fang, L.2
Zimmer, J.3
Baskys, A.4
-
49
-
-
33645091628
-
Glutamate receptors on human melanocytes regulate the expression of MiTF
-
Hoogduijn MJ, Hitchcock IS, Smit NP, Gillbro JM, Schallreuter KU, Genever PG. Glutamate receptors on human melanocytes regulate the expression of MiTF. Pigment Cell Res 2006; 19: 58-67.
-
(2006)
Pigment Cell Res
, vol.19
, pp. 58-67
-
-
Hoogduijn, M.J.1
Hitchcock, I.S.2
Smit, N.P.3
Gillbro, J.M.4
Schallreuter, K.U.5
Genever, P.G.6
-
50
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl J Med 2012; 367: 1694-1703.
-
(2012)
New Engl J Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
Gonzalez, R.4
Kefford, R.F.5
Sosman, J.6
-
51
-
-
77956211421
-
The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, beta-arrestin-1-dependent ERK phosphorylation
-
Emery AC, Pshenichkin S, Takoudjou GR, Grajkowska E, Wolfe BB, Wroblewski JT et al. The protective signaling of metabotropic glutamate receptor 1 is mediated by sustained, beta-arrestin-1-dependent ERK phosphorylation. J Biol Chem 2010; 285: 26041-26048.
-
(2010)
J Biol Chem
, vol.285
, pp. 26041-26048
-
-
Emery, A.C.1
Pshenichkin, S.2
Takoudjou, G.R.3
Grajkowska, E.4
Wolfe, B.B.5
Wroblewski, J.T.6
-
52
-
-
84900426582
-
Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
-
Edward HJ, Kevin Basile K, Aplin AE. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res 2014; 12: 795-802.
-
(2014)
Mol Cancer Res
, vol.12
, pp. 795-802
-
-
Edward, H.J.1
Kevin Basile, K.2
Aplin, A.E.3
-
53
-
-
84884203979
-
Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells
-
Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K et al. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene 2013; 32: 4366-4376.
-
(2013)
Oncogene
, vol.32
, pp. 4366-4376
-
-
Martino, J.J.1
Wall, B.A.2
Mastrantoni, E.3
Wilimczyk, B.J.4
La Cava, S.N.5
Degenhardt, K.6
|